Changes in Pregabalin Dispensing to Australians with Workers' Compensation Claims for Low Back Pain Following the Listing of Pregabalin on the Pharmaceutical Benefits Scheme.

The data only captured medicines funded by workers' compensation, missing those paid for by private insurance or out-of-pocket. The sample was restricted to workers with claims involving at least two weeks off work, potentially excluding milder cases. Few workers were dispensed pregabalin in the pre-listing group, which may reduce the precision of estimates for that period. The study could not determine if the increase was due to the subsidy itself or broader trends in prescribing and marketing.

The study was funded by the National Health and Medical Research Council and Monash University. No specific commercial conflicts of interest with drug manufacturers were declared in the provided text, though the discussion notes manufacturer-led education campaigns occurred during the study period.

Do not interpret the increase in pregabalin dispensing as evidence that the drug is effective for low back pain. The study reports changes in availability and cost, not clinical outcomes, and the introduction notes that gabapentinoids are not effective for this condition.